Minimal residual disease monitored after induction therapy by rq-pcr can contribute to tailor treatment of patients with t(8;21) runx1-runx1t1 rearrangement

Martina Pigazzi; Elena Manara; Barbara Buldini; Valzerda Beqiri; Valeria Bisio; Claudia Tregnago; Roberto Rondelli; Riccardo Masetti; Maria Caterina Putti; Franca Fagioli; Carmelo Rizzari; Andrea Pession; Franco Locatelli; Giuseppe Basso

doi:10.3324/haematol.2014.114579

Minimal residual disease monitored after induction therapy by rq-pcr can contribute to tailor treatment of patients with t(8;21) runx1-runx1t1 rearrangement

Martina Pigazzi, Elena Manara, Barbara Buldini, Valzerda Beqiri, Valeria Bisio, Claudia Tregnago, Roberto Rondelli, Riccardo Masetti, Maria Caterina Putti, Franca Fagioli, Carmelo Rizzari, Andrea Pession, Franco Locatelli, Giuseppe Basso

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Lingua originale	English
pagine (da-a)	e99-e101
Rivista	Haematologica
Volume	100
DOI	https://doi.org/10.3324/haematol.2014.114579
Stato di pubblicazione	Pubblicato - 2015

Keywords

AIEOPt(8
21)
AML
AML1-ETORUNX1-RUNX1T1
RQ-PCR
Inv(16)
Molecular MRD
Pediatric
CBFB-MYH11

Accesso al documento

10.3324/haematol.2014.114579

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Pigazzi, M., Manara, E., Buldini, B., Beqiri, V., Bisio, V., Tregnago, C., Rondelli, R., Masetti, R., Caterina Putti, M., Fagioli, F., Rizzari, C., Pession, A., Locatelli, F., & Basso, G. (2015). Minimal residual disease monitored after induction therapy by rq-pcr can contribute to tailor treatment of patients with t(8;21) runx1-runx1t1 rearrangement. Haematologica, 100, e99-e101. https://doi.org/10.3324/haematol.2014.114579

@article{210864044dbe4093914e8f339c7a2876,

title = "Minimal residual disease monitored after induction therapy by rq-pcr can contribute to tailor treatment of patients with t(8;21) runx1-runx1t1 rearrangement",

keywords = "AIEOPt(8, 21), AML, AML1-ETORUNX1-RUNX1T1, RQ-PCR, Inv(16), Molecular MRD, Pediatric, CBFB-MYH11, AIEOPt(8, 21), AML, AML1-ETORUNX1-RUNX1T1, RQ-PCR, Inv(16), Molecular MRD, Pediatric, CBFB-MYH11",

author = "Martina Pigazzi and Elena Manara and Barbara Buldini and Valzerda Beqiri and Valeria Bisio and Claudia Tregnago and Roberto Rondelli and Riccardo Masetti and {Caterina Putti}, Maria and Franca Fagioli and Carmelo Rizzari and Andrea Pession and Franco Locatelli and Giuseppe Basso",

year = "2015",

doi = "10.3324/haematol.2014.114579",

language = "English",

volume = "100",

pages = "e99--e101",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

}

Pigazzi, M, Manara, E, Buldini, B, Beqiri, V, Bisio, V, Tregnago, C, Rondelli, R, Masetti, R, Caterina Putti, M, Fagioli, F, Rizzari, C, Pession, A, Locatelli, F & Basso, G 2015, 'Minimal residual disease monitored after induction therapy by rq-pcr can contribute to tailor treatment of patients with t(8;21) runx1-runx1t1 rearrangement', Haematologica, vol. 100, pagg. e99-e101. https://doi.org/10.3324/haematol.2014.114579

TY - JOUR

T1 - Minimal residual disease monitored after induction therapy by rq-pcr can contribute to tailor treatment of patients with t(8;21) runx1-runx1t1 rearrangement

AU - Pigazzi, Martina

AU - Manara, Elena

AU - Buldini, Barbara

AU - Beqiri, Valzerda

AU - Bisio, Valeria

AU - Tregnago, Claudia

AU - Rondelli, Roberto

AU - Masetti, Riccardo

AU - Caterina Putti, Maria

AU - Fagioli, Franca

AU - Rizzari, Carmelo

AU - Pession, Andrea

AU - Locatelli, Franco

AU - Basso, Giuseppe

PY - 2015

Y1 - 2015

KW - AIEOPt(8

KW - 21)

KW - AML

KW - AML1-ETORUNX1-RUNX1T1

KW - RQ-PCR

KW - Inv(16)

KW - Molecular MRD

KW - Pediatric

KW - CBFB-MYH11

KW - AIEOPt(8

KW - 21)

KW - AML

KW - AML1-ETORUNX1-RUNX1T1

KW - RQ-PCR

KW - Inv(16)

KW - Molecular MRD

KW - Pediatric

KW - CBFB-MYH11

UR - http://hdl.handle.net/10807/229173

U2 - 10.3324/haematol.2014.114579

DO - 10.3324/haematol.2014.114579

M3 - Article

SN - 0390-6078

VL - 100

SP - e99-e101

JO - Haematologica

JF - Haematologica

ER -